#AAIC17

1 stories · following the connections

Business

Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate

By Nasdaq OMXJul 19, 2017, 8:35 AM UTC